Registration Dossier

Administrative data

Description of key information

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Data waiving:
other justification
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via inhalation route

Link to relevant study records
Reference
Endpoint:
acute toxicity: inhalation
Data waiving:
other justification
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Link to relevant study records
Reference
Endpoint:
acute toxicity: dermal
Data waiving:
other justification
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Justification for selection of acute toxicity – oral endpoint
According to Regulation (EC) 1907/2009 Annex VIII point 8.5 column 2, the study on acute toxicity via the oral route should not be conducted since divanadium tris(sulphate) is corrosive to the skin (pH < 0).

Justification for selection of acute toxicity – inhalation endpoint
According to Regulation (EC) 1907/2009 Annex VIII point 8.5 column 2, the study on acute toxicity via inhalation should not be conducted since divanadium tris(sulphate) is corrosive to the skin (pH < 0).

Justification for selection of acute toxicity – dermal endpoint
According to Regulation (EC) 1907/2009 Annex VIII point 8.5 column 2, the study on acute toxicity via the dermal route should not be conducted since divanadium tris(sulphate) is corrosive to the skin (pH < 0).

Justification for classification or non-classification

No (valid) studies are available in the literature that states that divanadium tris(sulphate) should be classified as acutely toxic via ingestion, inhalation and after contact with skin. However, since divanadium tris(sulphate) is classified as corrosive to skin, Cat. 1B and classified as seriously damage to eyes by worst case considerations (pH < 2), in-vivo acute toxicity studies do not need to be conducted in accordance with section 8.5, column 2, Annex VIII of Regulation (EC) 1907/2006.

Since, there is no evidence that divanadium tris(sulphate) is acutely toxic via ingestion, inhalation and after contact with skin, divanadium tris(sulphate) should not be classified as acutely toxic.

Specific target organ toxicant (STOT) – single exposure

The classification criteria according to Regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – single exposure, oral, inhalation, or dermal are not met (see discussion above). Hence, no C&L is required for divanadium tris(sulphate).